Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
复制标题
微透析-HPLC 用于帕金森病患者血浆左旋多巴和代谢物监测。
作者：
S. Dethy;M. Laute;N. Van Blercom;P. Damhaut;S. Goldman;J. Hildebrand
采用体外微透析-高效液相色谱法测定晚期帕金森病患者血浆中左旋多巴（L-DOPA）及其代谢产物的浓度。在口服卡比多巴/L-DOPA（25/100 mg、12.5/125 mg和50/200 mg）后0、30、60、90、120和150 min采集血样并进行临床评价。左旋多巴和代谢物的体外回收率范围为22%至36%。发现透析液和周围介质中的代谢物浓度之间存在线性相关性。左旋多巴剂量与血浆左旋多巴和高香草酸浓度呈显著正相关（P < 0.04）。L-DOPA给药后60分钟临床反应最大。阈值L-DOPA血浆浓度平均为7.74 +/- 3.3 mumol/L。L-DOPA峰值浓度越高，运动效应越长（P < 0.01）。微透析-HPLC是容易适用的，可重复的，并允许监测血浆左旋多巴和代谢物在帕金森病患者。
We used in vitro microdialysis-HPLC to determine L-3,4-dihydroxyphenylalanine (L-DOPA) and its metabolites in plasma of patients with advanced Parkinson disease. Blood samples and clinical evaluations were obtained 0, 30, 60, 90, 120, and 150 min after oral administration of carbidopa/L-DOPA (25/100 mg, 12.5/125 mg, and 50/200 mg). In vitro recoveries for L-DOPA and metabolites ranged from 22% to 36%. Linear correlation was found between metabolite concentrations in the dialysate and in the surrounding medium. There was a significant positive correlation between L-DOPA dose and plasma concentration of L-DOPA and homovanillic acid (P < 0.04). Clinical response was maximum 60 min after L-DOPA administration. Threshold L-DOPA plasma concentration averaged 7.74 +/- 3.3 mumol/L. Motor effect is longer with the highest L-DOPA peak concentration (P < 0.01). Microdialysis-HPLC is readily applicable, reproducible, and allows monitoring of plasma L-DOPA and metabolites in parkinsonian patients.